These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

326 related items for PubMed ID: 9030661

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Cross-protection against Leishmania donovani but not L. Braziliensis caused by vaccination with L. Major soluble promastigote exogenous antigens in BALB/c mice.
    Tonui WK, Titus RG.
    Am J Trop Med Hyg; 2007 Mar; 76(3):579-84. PubMed ID: 17360887
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Prevalence of antibodies and cell mediated immune response against Leishmania major in feral nonhuman primates from Kenya.
    Gicheru MM, Jeneby MM, Macharia JC, Carlsson HE, Suleman MA.
    Acta Trop; 2009 Feb; 109(2):136-40. PubMed ID: 18983806
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Immunization with the hybrid protein vaccine, consisting of Leishmania major cysteine proteinases Type I (CPB) and Type II (CPA), partially protects against leishmaniasis.
    Zadeh-Vakili A, Taheri T, Taslimi Y, Doustdari F, Salmanian AH, Rafati S.
    Vaccine; 2004 May 07; 22(15-16):1930-40. PubMed ID: 15121305
    [Abstract] [Full Text] [Related]

  • 8. Comparative assessment of a DNA and protein Leishmania donovani gamma glutamyl cysteine synthetase vaccine to cross-protect against murine cutaneous leishmaniasis caused by L. major or L. mexicana infection.
    Campbell SA, Alawa J, Doro B, Henriquez FL, Roberts CW, Nok A, Alawa CB, Alsaadi M, Mullen AB, Carter KC.
    Vaccine; 2012 Feb 08; 30(7):1357-63. PubMed ID: 22210224
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Prophylactic efficacy of high-molecular-weight antigenic fractions of a recent clinical isolate of Leishmania donovani against visceral leishmaniasis.
    Tripathi P, Gupta SK, Sinha S, Sundar S, Dube A, Naik S.
    Scand J Immunol; 2008 Nov 08; 68(5):492-501. PubMed ID: 18803606
    [Abstract] [Full Text] [Related]

  • 11. Protection against cutaneous leishmaniasis in outbred vervet monkeys using a recombinant histone H1 antigen.
    Masina S, M Gicheru M, Demotz SO, Fasel NJ.
    J Infect Dis; 2003 Oct 15; 188(8):1250-7. PubMed ID: 14551897
    [Abstract] [Full Text] [Related]

  • 12. Vaccination with a plasmid DNA cocktail encoding the nucleosomal histones of Leishmania confers protection against murine cutaneous leishmaniosis.
    Iborra S, Soto M, Carrión J, Alonso C, Requena JM.
    Vaccine; 2004 Sep 28; 22(29-30):3865-76. PubMed ID: 15364433
    [Abstract] [Full Text] [Related]

  • 13. Long-lasting protection against canine visceral leishmaniasis using the LiESAp-MDP vaccine in endemic areas of France: double-blind randomised efficacy field trial.
    Lemesre JL, Holzmuller P, Gonçalves RB, Bourdoiseau G, Hugnet C, Cavaleyra M, Papierok G.
    Vaccine; 2007 May 22; 25(21):4223-34. PubMed ID: 17395339
    [Abstract] [Full Text] [Related]

  • 14. Vaccination of vervet monkeys against cutaneous leishmaniosis using recombinant Leishmania 'major surface glycoprotein' (gp63).
    Olobo JO, Anjili CO, Gicheru MM, Mbati PA, Kariuki TM, Githure JI, Koech DK, McMaster WR.
    Vet Parasitol; 1995 Dec 22; 60(3-4):199-212. PubMed ID: 8747903
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Comparative susceptibility of African green monkeys (Cercopithecus aethiops) to experimental infection with Leishmania leishmania donovani and Leishmania leishmania infantum.
    Binhazim AA, Shin SS, Chapman WL, Olobo J.
    Lab Anim Sci; 1993 Feb 22; 43(1):37-47. PubMed ID: 8459677
    [Abstract] [Full Text] [Related]

  • 17. Vaccination with a novel recombinant Leishmania antigen plus MPL provides partial protection against L. donovani challenge in experimental model of visceral leishmaniasis.
    Bhardwaj S, Vasishta RK, Arora SK.
    Exp Parasitol; 2009 Jan 22; 121(1):29-37. PubMed ID: 18983842
    [Abstract] [Full Text] [Related]

  • 18. An experimental vaccine providing heterologous protection for Leishmania species in murine model.
    Bebars MA, el Serougi AO, Makled KM, Mikhael EM, Abou Gamra MM, el Sherbiny M, Mohareb AW, Mohammed EA.
    J Egypt Soc Parasitol; 2000 Apr 22; 30(1):137-56. PubMed ID: 10786026
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Vaccination with recombinant Leishmania donovani gamma-glutamylcysteine synthetase fusion protein protects against L. donovani infection.
    Henriquez FL, Campbell SA, Roberts CW, Mullen AB, Burchmore R, Carter KC.
    J Parasitol; 2010 Oct 22; 96(5):929-36. PubMed ID: 20950100
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.